JNJ stock

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

December 16, 2025 — Johnson & Johnson stock (NYSE: JNJ) is trading lower on Tuesday after pushing to fresh highs earlier this week, as investors weigh a mix of pipeline momentum, legal headlines, and an approaching earnings update that could

16 December 2025

Johnson & Johnson Stock After Hours (Dec. 15, 2025): JNJ Rises on FDA Priority Voucher — What to Know Before Tuesday’s Open

Johnson & Johnson (NYSE: JNJ) shares finished Monday, December 15, 2025 higher and held modest gains in extended trading — a notable showing for a defensive blue chip as investors brace for a data-heavy week and shifting rate expectations. JNJ

16 December 2025

FDA Updates · Financial Analysis · Investing · NYSE:JNJ · Pharma News · Stock Market

Johnson & Johnson (JNJ) Stock News Today, Forecasts and Analyst Targets (Dec. 12, 2025)

Published: December 12, 2025 Johnson & Johnson stock (NYSE: JNJ) is ending the week in the spotlight as shares hover near record territory, helped by a steady stream of analyst target updates, fresh late-stage clinical data disclosures, and a clearer

12 December 2025

Financial News · Investment Analysis · Johnson & Johnson · NYSE:JNJ · Stock Forecasts · Stock Market

Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Key Takeaways Below, we’ll walk through what happened to Johnson & Johnson stock after the bell on December 9 and what investors should watch before the U.S. market opens on Wednesday, December 10, 2025. 1. How Johnson & Johnson Stock

10 December 2025

Cancer Research · Dividends · Health News · Investment Tips · NYSE:JNJ · Stock Market

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Published: December 8, 2025 – This article is for informational purposes only and is not financial advice. Key Takeaways JNJ Stock Today: Price, Performance and Dividend Johnson & Johnson (NYSE: JNJ) is trading around $202–203 per share in New York

8 December 2025

Financial Forecasts · Investment Strategies · Market Trends · NYSE:JNJ · Pharmaceuticals · Stock Analysis

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Published: December 6, 2025 – For information only, not investment advice. Johnson & Johnson stock (NYSE: JNJ) is ending the first week of December 2025 just below record territory after a powerful year-long rally, driven by a string of earnings

6 December 2025

Cancer Research · Investment Analysis · Legal News · NYSE:JNJ · Pharmaceuticals · Stock Market

Johnson & Johnson (JNJ) Stock on December 4, 2025: Price Action, Latest News, Analyst Targets and 2026 Outlook

Published: December 4, 2025 Johnson & Johnson (NYSE: JNJ) remains one of 2025’s standout defensive stocks. After a powerful run driven by stronger pharma growth, MedTech momentum and a string of acquisitions, the healthcare giant now trades close to record

4 December 2025

Financial Outlook · Investment News · JNJ Analysis · Price Forecast · Stock Market

Johnson & Johnson (JNJ) Stock News & Forecast: EU Drug Approval, $3B Cancer Deal and Dividend Strength – December 1, 2025

As of December 1, 2025. This article is for information only and is not investment advice. JNJ stock today: riding near record highs after a huge 2025 rally Johnson & Johnson (NYSE: JNJ) stock is trading close to its 52‑week

1 December 2025

Cancer Research · Dividend Stocks · Investment News · NYSE:JNJ · Pharma Industry · Stock Market

Johnson & Johnson (JNJ) Stock Near Record Highs: Is the $500 Billion Healthcare Giant Still a Buy in 2025?

Updated: November 30, 2025 Johnson & Johnson stock has quietly turned into one of 2025’s big winners. After years of trading like a sleepy defensive name, JNJ has gone on an 11‑ to 13‑day winning streak, pushed its market capitalization

30 November 2025

Company Analysis · Financial News · Healthcare Stocks · Investing · NYSE:JNJ · Stock Market

Johnson & Johnson Stock (JNJ) Near Record Highs: Earnings Momentum, Spin‑Off Plans and Talc Risks in 2025

Published: November 29, 2025 – This article is for information only and is not financial advice. JNJ stock today: a mega‑cap back in the spotlight Johnson & Johnson stock (NYSE: JNJ) is ending November 2025 right up against its all‑time

29 November 2025

Earnings Reports · Healthcare Sector · Investment Strategies · NYSE:JNJ · Risk Analysis · Stock Market

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Updated: November 28, 2025 Johnson & Johnson (JNJ) is closing out 2025 as one of the standout “defensive” winners in the U.S. market. The stock is trading just below a fresh 52‑week high around $205–$208 per share, giving the healthcare

28 November 2025

Corporate Strategy · Investment Analysis · Legal Risks · Pharmaceuticals · Stock Market

Johnson & Johnson (JNJ) Stock Today – November 26, 2025: 12‑Day Rally Pushes Shares Toward $500 Billion Valuation

Johnson & Johnson (NYSE: JNJ) is quietly turning into one of 2025’s standout mega‑cap stories. By this afternoon on Wednesday, November 26, J&J shares were trading around $207 per share, up modestly on the day and hovering near their all‑time

26 November 2025

Company Analysis · Financial News · Investments · Market Trends · NYSE:JNJ · Stock Market